Loading...
Back to narrative

KRSNAA: Board Actions And Stable Margins Will Shape A Measured Outlook

Government Delays And Cost Pressures Will Challenge Diagnostics Optimistically

KRSNAA logo
KRSNAA
AnalystLowTarget
Not Invested
Published 24 Aug 2025

Update shared on 13 Dec 2025

Fair value Decreased 15%
n/a
n/a
AnalystLowTarget's Fair Value
n/a
Loading
1Y
-20.5%
7D
-2.0%

Narrative Update

Analysts have trimmed their price target on Krsnaa Diagnostics from ₹949 to ₹803.5, reflecting a more conservative valuation multiple, even as forecasts for revenue growth and profit margins remain broadly resilient.

What's in the News

  • Board meeting scheduled for November 7, 2025, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).
  • Board meeting set for November 12, 2025, with agenda items yet to be detailed (company filing).
  • Board meeting planned for December 12, 2025, to consider issuance of unlisted non convertible debentures on a private placement basis (company filing).

Valuation Changes

  • Fair Value: reduced significantly from ₹949.0 to ₹803.5, indicating a more conservative price target.
  • Discount Rate: risen marginally from 12.73% to 12.76%, implying a slightly higher required return.
  • Revenue Growth: eased slightly from 25.85% to 25.78%, reflecting a near unchanged growth outlook.
  • Net Profit Margin: improved moderately from 14.06% to 14.51%, suggesting better expected profitability.
  • Future P/E: declined significantly from 21.0x to 16.8x, pointing to a lower valuation multiple applied to future earnings.

Have other thoughts on Krsnaa Diagnostics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.